SNSE
Sensei Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.85
−22.28%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | (4.9M) | — | — | — | — |
| Cost of Revenue | 128.1M | — | 551.0K | 571.0K | 1.8M |
| Gross Profit | (133.0M) | — | (551.0K) | (571.0K) | (1.8M) |
| Operating Expenses | |||||
| R&D Expense | 25.2M | 11.0M | 18.6M | 18.3M | 29.6M |
| SG&A Expense | 27.5M | 11.3M | 12.5M | 18.8M | 17.7M |
| General & Admin Expense | 27.5M | 11.3M | — | 18.7M | — |
| Selling & Marketing Expense | — | — | — | 100.0K | — |
| Other Expenses | — | — | — | (571.0K) | — |
| Total Operating Expenses | 52.7M | 22.3M | 31.1M | 36.5M | 47.3M |
| Cost and Expenses | 180.8M | 22.3M | 31.7M | 37.1M | 49.1M |
| Operating Income (EBIT) | (185.6M) | (22.3M) | (31.7M) | (37.1M) | (49.1M) |
| Non-Operating | |||||
| Interest Income | 1.2M | 1.2M | 2.5M | 3.6M | 1.8M |
| Interest Expense | 19.0K | 32.0K | 90.0K | 144.0K | 219.0K |
| Net Interest Income | 1.2M | 1.2M | 2.5M | 3.5M | 1.6M |
| Other Non-Op Income/Expense | 1.2M | 1.2M | 1.5M | 3.0M | 532.0K |
| Non-Operating Income (excl Interest) | (1.2M) | (1.2M) | (1.6M) | (100.0K) | (751.0K) |
| EBT (Pre-Tax Income) | (184.5M) | (21.1M) | (30.2M) | (34.1M) | (48.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (184.5M) | (21.1M) | (30.2M) | (34.1M) | (48.6M) |
| Earnings from Cont. Ops | (184.5M) | (21.1M) | (30.2M) | (34.1M) | (48.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (184.5M) | (21.1M) | (30.2M) | (34.1M) | (48.6M) |
| Per Share | |||||
| Basic EPS | ($147.90) | ($16.72) | ($1.20) | ($1.22) | ($1.58) |
| Diluted EPS | ($147.90) | ($16.72) | ($1.20) | ($1.22) | ($1.58) |
| Revenue Per Share | ($3.75) | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.3M | 1.3M | 25.1M | 28.0M | 30.7M |
| Diluted Shares Outstanding | 1.3M | 1.3M | 25.1M | 28.0M | 30.7M |
| Profitability Metrics | |||||
| EBITDA | (184.3M) | (20.9M) | (29.5M) | (33.4M) | (46.6M) |
| D&A | 135.0K | 139.0K | 551.0K | 3.7M | 1.8M |
| EBIT | (184.4M) | (21.1M) | (30.1M) | (37.0M) | (48.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026